◀ Back to MAPK14
MAP2K6 — MAPK14
Pathways - manually collected, often from reviews:
-
OpenBEL Selventa BEL large corpus:
MAPK14
→
MAP2K6
(directlyIncreases, MAP2K6 Activity, MAPK14 Activity)
Evidence: Transfection of HeLa cells with MKK6b(E), a constitutively active specific upstream activator of p38, led to a potent inhibition of GR activation of the MMTV promoter-driven luciferase construct.
-
OpenBEL Selventa BEL large corpus:
MAPK14
→
MAP2K6
(directlyIncreases, MAPK14 Activity)
Evidence: 7750576;16083285;15674326;15735648;10781613;15972258
-
OpenBEL Selventa BEL large corpus:
MAPK14
→
MAP2K6
(directlyIncreases, MAPK14 Activity)
Evidence: 15592455;16083285;15659558;15674326;10781613;15972258;15735649;17081983
-
KEGG Osteoclast differentiation:
MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, activation)
-
KEGG Toll-like receptor signaling pathway:
MAP2K3/MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, phosphorylation)
-
KEGG Fc epsilon RI signaling pathway:
MAP2K3/MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, activation)
-
KEGG GnRH signaling pathway:
MAP2K3/MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, activation)
-
KEGG Amyotrophic lateral sclerosis (ALS):
MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, activation)
-
KEGG MAPK signaling pathway:
MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, phosphorylation)
-
KEGG Toxoplasmosis:
MAP2K3/MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, activation)
-
KEGG Influenza A:
MAP2K3/MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, activation)
-
NCI Pathway Database IL6-mediated signaling events:
p38alpha-beta (MAPK14/MAPK11)
→
MKK6 (MAP2K6)
(modification, collaborate)
Bode et al., Biol Chem 2001
-
NCI Pathway Database FAS (CD95) signaling pathway:
p38alpha-beta (MAPK14/MAPK11)
→
MKK6 (MAP2K6)
(modification, collaborate)
Toyoshima et al., J Cell Biol 1997
Evidence: assay
-
NCI Pathway Database CXCR3-mediated signaling events:
p38alpha-beta (MAPK14/MAPK11)
→
MKK3-MKK6-active (MAP2K3/MAP2K6)
(modification, collaborate)
Petrai et al., Int J Biochem Cell Biol 2008
Evidence: assay
-
NCI Pathway Database Trk receptor signaling mediated by the MAPK pathway:
MKK3-MKK6-active (MAP2K3/MAP2K6)
→
p38 alpha (MAPK14)
(modification, activates)
Shi et al., J Biol Chem 2005, Xing et al., Mol Cell Biol 1998*
Evidence: mutant phenotype, assay, other species
-
NCI Pathway Database CDC42 signaling events:
MKK3-MKK6-active (MAP2K3/MAP2K6)
→
p38 alpha (MAPK14)
(modification, activates)
Wery-Zennaro et al., Oncogene 2000*, Yamauchi et al., J Biol Chem 2001*, Lee et al., J Biol Chem 2001*, Seo et al., J Biol Chem 2004*, Chan et al., J Biol Chem 2008*, Zhang et al., J Biol Chem 1995
Evidence: mutant phenotype, assay
-
NCI Pathway Database IL12-mediated signaling events:
MKK3-MKK6-active (MAP2K3/MAP2K6)
→
p38 alpha (MAPK14)
(modification, activates)
Rincón et al., EMBO J 1998*
Evidence: mutant phenotype
-
NCI Pathway Database Regulation of p38-alpha and p38-beta:
MKK6 (MAP2K6)
→
p38 alpha (MAPK14)
(modification, activates)
Han et al., J Biol Chem 1993*, Han et al., Science 1994*, Lee et al., Nature 1994*, Raingeaud et al., Mol Cell Biol 1996, Keesler et al., Protein Expr Purif 1998*
Evidence: mutant phenotype, assay, other species
-
NCI Pathway Database Signaling events mediated by VEGFR1 and VEGFR2:
MKK6 (MAP2K6)
→
p38 alpha (MAPK14)
(modification, activates)
Meyer et al., Mol Cell Biol 2011
Evidence: mutant phenotype
-
NCI Pathway Database RAC1 signaling pathway:
MKK3-MKK6-active (MAP2K3/MAP2K6)
→
p38 alpha (MAPK14)
(modification, activates)
Alsayed et al., J Biol Chem 2001*
Evidence: assay
-
NCI Pathway Database Regulation of Androgen receptor activity:
MKK6 (MAP2K6)
→
p38 alpha (MAPK14)
(modification, activates)
Gioeli et al., Mol Endocrinol 2006*
Evidence: mutant phenotype
-
Reactome Reaction:
MAP2K6
→
MAPK14
(reaction)
New et al., Mol Biol Cell 2003*, Sun et al., Cell 2007, Raingeaud et al., J Biol Chem 1995, Raingeaud et al., Mol Cell Biol 1996, New et al., EMBO J 1998
-
WikiPathways MAPK Cascade:
MAP2K6
→
MAPK14/MAPK12
(activation)
-
WikiPathways MicroRNAs in cardiomyocyte hypertrophy:
MAP2K3/MAP2K6
→
MAPK14
(activation)
-
WikiPathways Structural Pathway of Interleukin 1 (IL-1):
MAP2K6
→
MAPK14
(activation)
-
WikiPathways p38 MAPK Signaling Pathway:
MAP2K6
→
MAPK14
(activation)
-
WikiPathways Cardiac Hypertrophic Response:
MAP2K6/MAP2K3
→
MAPK14
(activation)
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
-
IRef Bind_translation Interaction:
MAP2K6
—
MAPK14
(experimental interaction detection)
Deacon et al., J Biol Chem 1999*
-
IRef Biogrid Interaction:
MAP2K6
—
MAPK14
(physical association, affinity chromatography technology)
Casar et al., EMBO J 2007*
-
IRef Biogrid Interaction:
MAP2K6
—
MAPK14
(direct interaction, pull down)
Xia et al., Genes Dev 1998*
-
IRef Biogrid Interaction:
MAP2K6
—
MAPK14
(direct interaction, enzymatic study)
Sanz-Moreno et al., Mol Cell Biol 2003*
-
IRef Biogrid Interaction:
MAP2K6
—
MAPK14
(direct interaction, enzymatic study)
Raingeaud et al., Mol Cell Biol 1996
-
IRef Biogrid Interaction:
MAP2K6
—
MAPK14
(direct interaction, enzymatic study)
Stein et al., J Biol Chem 1996*
-
IRef Biogrid Interaction:
MAP2K6
—
MAPK14
(direct interaction, enzymatic study)
Chen et al., J Biol Chem 2001*
-
IRef Hprd Interaction:
MAP2K6
—
MAPK14
(in vivo)
Sullivan et al., Biochemistry 2005*, Doza et al., FEBS Lett 1995*, Raingeaud et al., Mol Cell Biol 1996, Stein et al., J Biol Chem 1996*, Xia et al., Genes Dev 1998*
-
IRef Hprd Interaction:
MAP2K6
—
MAPK14
(in vitro)
Sullivan et al., Biochemistry 2005*, Doza et al., FEBS Lett 1995*, Raingeaud et al., Mol Cell Biol 1996, Stein et al., J Biol Chem 1996*, Xia et al., Genes Dev 1998*
-
IRef Innatedb Interaction:
MAP2K6
—
MAPK14
(unknown, -)
ter Haar et al., J Biol Chem 2007
-
IRef Innatedb Interaction:
MAP2K6
—
MAPK14
(unknown, -)
Raingeaud et al., Mol Cell Biol 1996
-
IRef Intact Interaction:
MAP2K6
—
MAPK14
(physical association, anti tag coimmunoprecipitation)
Casar et al., EMBO J 2007*
-
IRef Ophid Interaction:
MAP2K6
—
MAPK14
(aggregation, confirmational text mining)
Stein et al., J Biol Chem 1996*
-
IRef Ophid Interaction:
MAP2K6
—
MAPK14
(aggregation, interologs mapping)
Brown et al., Bioinformatics 2005
Text-mined interactions from Literome
Martel-Pelletier et al., Arthritis Rheum 1999
(Osteoarthritis) :
Within minutes, IL-17 induced the phosphorylation of
mitogen activated protein kinase kinase-1/2 ( MEK-1/2 ), -3/6 ( MKK-3/6 ), p44/42, p38, and inhibitor of nuclear factor kappaB ( I kappaB)-alpha, as well as the
activation of
mitogen activated protein kinase activated protein kinase-1 and -2 ( MAPKAPK-1 and -2 )
Tu et al., J Biomed Sci 2001
(Carcinoma, Hepatocellular) :
On the other hand, PD98059, a specific inhibitor of
mitogen activated protein kinase kinase ,
blocks TPA induced
MAPK activation but has no effect on TPA induced tyrosine phosphorylation
Huang et al., Biochem Biophys Res Commun 2003
:
MAP3Ks are components of a three tiered protein kinase pathway in which a MAP3K phosphorylates and activates a
mitogen activated protein kinase kinase ( MAP2K ), which in turn
activates a
mitogen activated protein kinase ( MAPK )
Wu et al., Free Radic Biol Med 2010
(Drug-Induced Liver Injury) :
This was followed by
activation of
MKK3/MKK6 and MKK4/MKK7 at 4-8 or 12h and then JNK/p38
MAPK at 8 to 12h
Lee et al., Nat Med 2011
(Obesity) :
Further, we show that
activation of p38
MAPK by expression of constitutively active
MAP kinase kinase 6 ( MKK6Glu ) greatly enhances nuclear translocation of Xbp1s, reduces endoplasmic reticulum stress and establishes euglycemia in severely obese and diabetic mice
Huwiler et al., Br J Pharmacol 1994
:
2. Both nucleotides stimulate phosphorylation and
activation of
mitogen activated protein kinase and a biphasic phosphorylation of the up-stream
mitogen activated protein kinase kinase
Daum et al., FEBS Lett 1998
:
Pervanadate inhibits
mitogen activated protein kinase kinase-1 in a
p38MAPK dependent manner